Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis

Ann Dermatol Venereol. 2023 Sep;150(3):243-245. doi: 10.1016/j.annder.2023.03.008. Epub 2023 May 23.

Authors

S Karaa¹, C Cassius², M Jachiet², T Mahevas², E Charvet², O Benveniste³, J-D Bouaziz²

Affiliations

¹ Dermatology Department and University of Paris, Saint-Louis Hospital, Paris, France. Electronic address: sabine.karaa@aphp.fr.
² Dermatology Department and University of Paris, Saint-Louis Hospital, Paris, France.
³ Internal Medicine Department and University of Paris, Pitié-Salpêtrière Hospital, Paris, France.

PMID: 37230890
DOI: 10.1016/j.annder.2023.03.008

No abstract available

Publication types

Letter

MeSH terms

Administration, Cutaneous
Dermatomyositis* / drug therapy
Humans
Janus Kinase 1
Skin

Substances

baricitinib
Janus Kinase 1